The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Andrew James Martin
No Relationships to Disclose
 
Robert Richard Zielinski
Honoraria - BMS; Pfizer; Roche/Genentech
Speakers' Bureau - BMSi; MSD Oncology
Research Funding - AstraZeneca (Inst); BMSi (Inst)
 
Alastair Thomson
Consulting or Advisory Role - MSD; Novartis
Speakers' Bureau - Genomic Health; Lilly; Novartis; Roche
Travel, Accommodations, Expenses - Astellas Pharma; BMS; EUSA Pharma; Ipsen; MSD
 
Thean Hsiang Tan
Speakers' Bureau - Ipsen; Janssen Oncology
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
 
M. Neil Reaume
Honoraria - AstraZeneca; EMD serono; Ipsen; Novartis; Pfizer
Research Funding - AstraZeneca
 
David William Pook
Honoraria - Bayer
Consulting or Advisory Role - Astellas Pharma; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Francis Parnis
Stock and Other Ownership Interests - Telix Pharmaceuticals
Consulting or Advisory Role - Ipsen; Janssen Oncology; Merck Serono
 
Scott A. North
Honoraria - Astellas Pharma; BMS; Janssen-Ortho; Merck; Pfizer; Roche Canada; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Pfizer; Roche Canada; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca
 
Gavin M. Marx
Honoraria - Janssen; Roche
Consulting or Advisory Role - Janssen; Roche
 
John McCaffrey
No Relationships to Disclose
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Nicola Jane Lawrence
Honoraria - MSD (Inst)
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Imagion Biosystems
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer
 
Mark Frydenberg
No Relationships to Disclose
 
Simon Chowdhury
Honoraria - Clovis Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Novartis; Pfizer
Speakers' Bureau - Janssen-Cilag; Pfizer
Research Funding - Sanofi/Aventis (Inst)
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination